HUP0500004A2 - Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény - Google Patents

Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény

Info

Publication number
HUP0500004A2
HUP0500004A2 HU0500004A HUP0500004A HUP0500004A2 HU P0500004 A2 HUP0500004 A2 HU P0500004A2 HU 0500004 A HU0500004 A HU 0500004A HU P0500004 A HUP0500004 A HU P0500004A HU P0500004 A2 HUP0500004 A2 HU P0500004A2
Authority
HU
Hungary
Prior art keywords
approx
metformin
hours
core
tablet
Prior art date
Application number
HU0500004A
Other languages
English (en)
Inventor
Pawan Seth
Benoit Schmidtt
Original Assignee
Biovail Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Laboratories Inc. filed Critical Biovail Laboratories Inc.
Publication of HUP0500004A2 publication Critical patent/HUP0500004A2/hu
Publication of HUP0500004A3 publication Critical patent/HUP0500004A3/hu
Publication of HU229962B1 publication Critical patent/HU229962B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya nyújtott felszabadulású tabletta formájúgyógyszerkészítmény, amely a következőket tartalmazza: (i) egytablettamag, amely a mag tömegére számolva kb. 70-99% metformint ésgyógyszerészetileg elfogadható excipienst vagy excipiensekettartalmaz, és (ii) egy metformin számára permeábilis bevonat, amelynyújtott felszabadulású tabletta kioldódási profilja olyan, hogy abenne lévő metformin felszabadulása kb. 2 óra után kb. 7-60%, kb. 4óra után kb. I5-90%, kb. 8 óra után kb. 50-100% és 12 óra után több,mint 75%. A találmány szerinti nyújtott felszabadulású gyógyszerészetitabletta magja adott esetben még egy duzzadóanyagot is tartalmaz és abevonat monomer pórusképző szertől mentes. Ó
HU0500004A 2001-12-04 2002-12-04 Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény HU229962B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/005,387 2001-12-04
US10/005,387 US20030118647A1 (en) 2001-12-04 2001-12-04 Extended release tablet of metformin
PCT/US2002/038599 WO2003047529A2 (en) 2001-12-04 2002-12-04 Extended release pharmaceutical tablet of metformin

Publications (3)

Publication Number Publication Date
HUP0500004A2 true HUP0500004A2 (hu) 2005-04-28
HUP0500004A3 HUP0500004A3 (en) 2012-09-28
HU229962B1 HU229962B1 (hu) 2015-03-30

Family

ID=21715581

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500004A HU229962B1 (hu) 2001-12-04 2002-12-04 Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény

Country Status (12)

Country Link
US (3) US20030118647A1 (hu)
EP (1) EP1460998B1 (hu)
AT (1) ATE460157T1 (hu)
AU (1) AU2002359582C1 (hu)
CA (1) CA2470747C (hu)
DE (1) DE60235648D1 (hu)
ES (1) ES2338536T3 (hu)
HU (1) HU229962B1 (hu)
MX (1) MXPA04005667A (hu)
NO (2) NO333929B1 (hu)
NZ (1) NZ533857A (hu)
WO (1) WO2003047529A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392705T3 (es) * 2000-10-02 2012-12-13 Usv Ltd. Composiciones farmacéuticas de liberación sostenida que contienen metformina y método para su producción
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
ES2627842T3 (es) * 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Formas de dosificación de liberación controlada
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2005123134A2 (en) * 2004-05-14 2005-12-29 Cadila Healthcare Limited A controlled release delivery system for metformin
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
KR100858848B1 (ko) * 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
WO2010026467A2 (en) * 2008-09-04 2010-03-11 Torrent Pharmaceuticals Ltd. Controlled release dosage form of high solubility active ingredient
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN103622930B (zh) * 2013-12-19 2015-06-10 石家庄市华新药业有限责任公司 一种盐酸二甲双胍缓释制剂及其制备方法
WO2016042567A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of metformin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2001A (en) * 1841-03-12 Sawmill
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CH672888A5 (hu) * 1986-11-07 1990-01-15 Mepha Ag
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
DK1092434T3 (da) * 1995-09-21 2004-07-26 Pharma Pass Ii Llc Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
DE19915420A1 (de) * 1999-04-06 2000-10-12 Basf Ag Stabilisierte Polyvinylpyrrolidon-Zubereitungen
US6338857B1 (en) * 2000-05-26 2002-01-15 Pharma Pass Llc Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
ATE460157T1 (de) 2010-03-15
NO20042822L (no) 2004-08-26
US20030170302A1 (en) 2003-09-11
EP1460998A2 (en) 2004-09-29
NO333929B1 (no) 2013-10-21
HU229962B1 (hu) 2015-03-30
EP1460998B1 (en) 2010-03-10
US20030118647A1 (en) 2003-06-26
AU2002359582C1 (en) 2008-11-13
CA2470747A1 (en) 2003-06-12
US20040161461A1 (en) 2004-08-19
WO2003047529A2 (en) 2003-06-12
AU2002359582A1 (en) 2003-06-17
WO2003047529A3 (en) 2003-10-30
CA2470747C (en) 2009-07-28
ES2338536T3 (es) 2010-05-10
AU2002359582B2 (en) 2007-01-18
NZ533857A (en) 2007-05-31
DE60235648D1 (de) 2010-04-22
EP1460998A4 (en) 2005-09-14
MXPA04005667A (es) 2005-06-17
HUP0500004A3 (en) 2012-09-28
NO20130984L (no) 2004-08-26

Similar Documents

Publication Publication Date Title
HUP0500004A2 (hu) Metformint tartalmazó nyújtott felszabadulású tabletta formájú gyógyszerkészítmény
HUP0402293A2 (hu) Fexofenadint tartalmazó szájban diszpergálódó tablettakészítmény, bevonatos granulátum és eljárás az előállítására
HUP0402328A2 (hu) Diabétesz mellitusz kezelésére szolgáló gyógyszerkészítmény
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
HUP0300698A2 (hu) N-acetil-p-aminofenol tartalmú készítmény
WO2004026256A3 (en) Sustained-release opioid formulations and methods of use
HUP0201907A2 (hu) Időzített kettős hatóanyag-leadású dózisformák, amelyek rövid ideig ható altatót vagy annak sóját tartalmazzák
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
HUP0303695A2 (hu) Módosított hatóanyag-leadású metil-fenidát készítmények és eljárás az elõállításukra
CY1105170T1 (el) Συνταγοποιηση απο του στοματος δοσολογιας αστραπιαιας - τηξης
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
HUP0202495A2 (hu) Orális alkalmazásra szolgáló stabil gyógyszerkészítmény
HUP0400475A2 (hu) Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
NO317747B1 (no) Farmasoytisk preparat samt anvendelse derav
BR9607234A (pt) Grânulos mucoadesivos uso dos mesmos processo para sua preparação composição farmâceutica e uso da mesma
HUP0300130A2 (en) Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
DE59908764D1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
MY127350A (en) Flash-melt oral dose formulations
MXPA04007437A (es) Sistema de suministro osmotico.
EE200300139A (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
NO963634D0 (no) Antihostepreparat inneholdende et antihostemiddel og benzydamin

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees